‘Osmosin’ (sodium indomethacin trihydrate) in the treatment of elderly patients with osteoarthritis

Authors:

Abstract
SummaryA 12-week, double-blind, multi-centre trial was carried out in 402 out-patients with osteoarthritis to compare the efficacy and tolerability of the osmotic-release formulation of indomethacin (‘Osmosin’) with that of indomethacin capsules. Data from a sub-set of 178 patients aged 60 years or over were analyzed separately. The results indicated that ‘Osmosin’, releasing the equivalent of 7 mg indomethacin per hour over approximately 10 hours, provided efficacy comparable to or better than that of indomethacin capsules (25 mg3-times daily) and had a better tolerance profile. Fewer patients treated with ‘Osmosin’ developed adverse experiences (p<0.05), especially central nervous system symptoms (p<0.05), and fewer were withdrawn from treatment because of adverse experiences (p<0.05). A reduction in the number of patients having gastro-intestinal symptoms was also identified. The majority of the patients maintained on one daily dose of ‘Osmosin’ had a good or excellent therapeutic response.

This publication has 16 references indexed in Scilit: